Skip To Main Content
Yingli Han on Muck Rack

Yingli Han

As seen in: Nature, Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingli

Contact Yingli, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia

|
By Qiwei Wang, Jingyi Li, Xin Zeng, Lina Liu, Huan Lu, Yin Zhao, Yan Huang, Rui Wang, Chen Wang, Yingli Han, Yishan Ye, Yanmin Zhao, Jimin Shi, Yi Luo, Weiyan Zheng, Yongxian Hu, Shibing Wang, Xiangmin Tong, He Huang, Shanshan Pei, Pengxu Qian
| Nature Verified
Abstract Acute myeloid leukemia (AML) remains challenging, especially for older or unfit individuals who develop resistance to venetoclax (VEN)-based regimens. Although TIM3 represents a promising AML target, clinical blockade has yielded suboptimal outcomes. Here, we develop VINCENT (VEN-integrated natural killer cell engager targeting TIM3), a therapeutic platform combining anti-CD16 and anti-TIM3 antibodies with nanoformulated VEN.
Open in Who Shared Issue with article?

Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy

|
By Delin Kong, TingTing Yang, Mengyu Zhao, Lin Yang, Ruirui Jing, Youqin Feng, Shaohui Shi, Zhouning Lin, Cong Wei, Rongrong Chen, Qiqi Zhang, Jiazhen Cui, Tianning Gu, Xiujian Wang, Xia Li, Xiaolin Yuan, Mingming Zhang, linghui Zhou, Houli Zhao, Ruimin Hong, Mi Shao, Xiaohui Si, Yingli Han, Shufen Wang, Xiangjun Zeng, Dawei Huo, Meng Zhang, Kejia Hu, Haiqiong Zheng, Guoqing Wei, Dongrui Wang, Yongxian Hu, Pengxu Qian, He Huang, Simao Huang, Zenan Cen
| Nature Verified
Abstract Long-term persistence of chimeric antigen receptor (CAR)-T cells is essential for durable therapeutic efficacy but the mechanisms underlying CAR-T cell dysfunction remain unclear.
Open in Who Shared Issue with article?

CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models

|
By Kai Shang, Deyu Huang, Jun Liu, Zebin Yu, Wei Bian, Yin Zhao, Lina Liu, Jie Jiang, Yajie Wang, Yanting Duan, Jingyu Ge, Shize Zhang, Chun Zhou, Yongxian Hu, Weiyan Zheng, Jie Sun, He Huang, Shanshan Pei, Pengxu Qian, Jiangqing Chen, Yingli Han
| Cell Reports Medicine Verified
Keywords: acute myeloid leukemia CD97 chimeric antigen receptor immunotherapy exhaustion Introduction Acute myeloid leukemia (AML) is a prevalent acute leukemia in adults, characterized by the blocked differentiation and abnormal proliferation of immature myeloid cells, leading to hematopoietic disorder and life-threatening cytopenia. The incidence rate of AML tends to increase gradually with age, along with a decline in overall survival.
Open in Who Shared Issue with article?
See all 3 articles